TOP TEN perturbations for 39292_r_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39292_r_at
Selected probe(set): 213301_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39292_r_at (213301_x_at) across 6674 perturbations tested by GENEVESTIGATOR:
echinomycin study 1 / deferoxamine study 5
Relative Expression (log2-ratio):-3.287096Number of Samples:3 / 3
Experimental | echinomycin study 1 |
Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:--- | |
Control | deferoxamine study 5 |
Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code: |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):3.2756004Number of Samples:2 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated p53HCT116 cell sample |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample
Relative Expression (log2-ratio):-3.2365484Number of Samples:2 / 4
Experimental | R547 study 1 (24h) |
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:--- | |
Control | vehicle (DMSO) treated DU145 cell sample |
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours. |
actinomycin D study 1 / mannitol treated A549 cell sample
Relative Expression (log2-ratio):-3.1322117Number of Samples:3 / 3
Experimental | actinomycin D study 1 |
A549 human lung cancer cells were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, actinomycin D (5 ug/mL final concentration) was added to the culture. ATC code: | |
Control | mannitol treated A549 cell sample |
A549 human lung cancer cells were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, mannitol (5% final concentration) was added to the culture. |
brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):3.0270348Number of Samples:3 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated HCT 116 cell sample |
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
precursor-B-ALL study 2 (MLL-rearranged) / precursor-B-ALL study 2 (TEL-AML1)
Relative Expression (log2-ratio):-2.8735723Number of Samples:4 / 21
Experimental | precursor-B-ALL study 2 (MLL-rearranged) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Dutch Childhood Oncology Group (DCOG). | |
Control | precursor-B-ALL study 2 (TEL-AML1) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Dutch Childhood Oncology Group (DCOG). |
influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):2.8588247Number of Samples:3 / 3
Experimental | influenza virus study 11 (A/H5N3) |
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
influenza virus study 9 (A/H9N2) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):2.8092403Number of Samples:3 / 3
Experimental | influenza virus study 9 (A/H9N2) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/Duck/Malaysia/01 (H9N2). Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample
Relative Expression (log2-ratio):2.702732Number of Samples:3 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) |
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated HCT 116 DICER1(-/-) cell sample |
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):2.6249104Number of Samples:2 / 2
Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |